Pfizer Reports Decent Third-Quarter Results; Loss of Exclusivity on Blockbuster Drug Lipitor Concerning
publication date: Nov 1, 2011
All things considered, we're less than thrilled with Pfizer. The firm will be losing exclusivity on its $10-billion-per-year blockbuster drug Lipitor at the end of November, and its earnings-per-share expansion is largely driven by buybacks. Though its valuation is compelling, there are better opportunities out there.
To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.